Fapon · 2 months ago
Senior/Staff Scientist , NGS Assay Development
GeneGenieDx is a biotech company focused on discovering novel biomarkers and translating them into clinical diagnostic products. They are seeking a passionate Senior/Staff Scientist to lead the development of next-generation sequencing (NGS) assays, leveraging expertise in RNA-sequencing and methylation sequencing to create innovative diagnostic techniques.
BiotechnologyHealth CareManufacturingMedical
Responsibilities
Experience in novel NGS method development
Experience in RNA-seq, Methylation sequencing, and single-cell RNA-seq
Deep knowledge of enzymes and molecular biology
Experience in cancer biology
Experience in working with challenging clinical specimens with low biomass such as stool and blood
Qualification
Required
Ph.D. in Biological Sciences such as molecular biology, genomics, and biochemistry
Experience in novel NGS method development
Experience in RNA-seq, Methylation sequencing, and single-cell RNA-seq
Deep knowledge of enzymes and molecular biology
Preferred
Experience in cancer biology
Experience in working with challenging clinical specimens with low biomass such as stool and blood
Benefits
Financial security through competitive compensation, incentives, and retirement plan
Health care and well-being programs including competitive medical, dental, vision & medical benefits.
Generous paid time off including vacation, sick time, & holidays
401(k) retirement savings with a company match
Other comprehensive voluntary benefits include but are not limited to pet insurance, life insurance, employee assistance program, discount programs, and many more.
We continue to optimize our benefits & wellness programs as we grow our organization to make sure they meet our diverse workforce needs.
The stability of a company with a record of strong financial performance year over year.
Company
Fapon
FAPON is a biotechnology company that provides IVD reagent raw material manufacturing and a one-stop solution.
Funding
Current Stage
Public CompanyTotal Funding
$1.74M2019-01-01Post Ipo Equity
2017-05-16Post Ipo Equity· $1.74M
2016-08-18IPO
Recent News
Research and Markets
2025-11-04
Company data provided by crunchbase